Diagnostic Center | May 20, 2024
Bristol Myers Squibb’s CAR T Cell Therapy Breyanzi approved by USFDA
95.7% of patients responded to Breyanzi in the TRANSCEND FL trial
95.7% of patients responded to Breyanzi in the TRANSCEND FL trial
At the recommended Phase 3 dose of 200 mg vepdegestrant in combination with palbociclib, patients achieved a median progression-free survival of 13.9 months
Pivotal OASIS 1 and 2 Phase III studies of investigational compound elinzanetant achieved a statistically significant reduction in frequency and severity of vasomotor symptoms
225Ac-PSMA-Trillium is an investigational next-generation PSMA-targeted alpha therapy with potential to treat patients with advanced metastatic prostate cancer
U.S. FDA has informed Moderna that due to administrative constraints, the agency will not complete its review of mRNA-1345 by the PDUFA date of May 12, 2024
First BTK inhibitor to show favourable trend in overall survival vs. standard-of-care chemoimmunotherapy in this setting
GAAP net loss of $1.2 billion and GAAP diluted EPS of $(3.07)
Late-breaker Phase 3 STRIDE-10 trial presented as an oral presentation at European Society of Clinical Microbiology and Infectious Diseases
Recommendation based on CAPItello-291 results which showed the Truqap combination reduced the risk of disease progression or death by 50%
Parexel will leverage Palantir’s Foundry and Artificial Intelligence Platform to further power its clinical data platform
Subscribe To Our Newsletter & Stay Updated
